Synthetic Glycopeptides from the Mucin Family as Potential Tools in Cancer Immunotherapy

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|6|6|491-517

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.6, Iss.6, 2006-09, pp. : 491-517

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeted Cancer Immunotherapy Using Ligands of the Tumor Necrosis Factor Super-Family

By  

Current Drug Targets, Vol. 10, Iss. 2, 2009-02 ,pp. : 94-103

Bentham Science Publishers

Access to resources Recommend Favorite

Fas ligand: a potential target for therapeutic induction of apoptosis and enhancing immunotherapy in cancer

By O'Connell J.  

Expert Opinion on Therapeutic Targets, Vol. 3, Iss. 4, 1999-12 ,pp. : 601-611

Informa Healthcare

Access to resources Recommend Favorite

Potential for novel MUC1 glycopeptide-specific antibody in passive cancer immunotherapy†

By Madsen Caroline B.   Wandall Hans H.   Pedersen Anders Elm  

Immunopharmacology and Immunotoxicology, Vol. 35, Iss. 6, 2013-12 ,pp. : 649-652

Informa Healthcare

Access to resources Recommend Favorite

Efficacy of Bacteria in Cancer Immunotherapy: Special Emphasis on the Potential of Mycobacterial Species

By  

Clinical Cancer Drugs, Vol. 3, Iss. 2, 2016-10 ,pp. : 100-108

Bentham Science Publishers

Access to resources Recommend Favorite

Efficacy of Bacteria in Cancer Immunotherapy: Special Emphasis on the Potential of Mycobacterial Species

By  

Clinical Cancer Drugs, Vol. 3, Iss. 2, 2016-10 ,pp. : 100-108

Bentham Science Publishers

Access to resources Recommend Favorite